Rare occurrence of ovarian hyperstimulation syndrome in oocyte donors

International Journal of Gynecology and Obstetrics

Volumn 52, Issue 3, 1996, Pages 259-262

  Sauer, M V ^a,b   Paulson, R J ^a   Lobo, R A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

Donor eggs; Oocyte donation; Ovarian hyperstimulation syndrome

Indexed keywords

ESTRADIOL; GONADORELIN AGONIST; HUMAN MENOPAUSAL GONADOTROPIN;

ADULT; ARTICLE; DISEASE SEVERITY; DONOR; DOWN REGULATION; ESTRADIOL BLOOD LEVEL; FEMALE; HUMAN; HYPOPHYSIS; INCIDENCE; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MENSTRUATION; OOCYTE DONATION; OVARY DISEASE; PRIORITY JOURNAL; TRANSVAGINAL ECHOGRAPHY;

EID: 0030031621     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/0020-7292(95)02587-1     Document Type: Article

References (27)

1. Bergh PA, Navot D. Ovarian hyperstimulation syndrome: a review of pathophysiology. J Assisted Reprod Genet 1992; 9: 429-438.
2. Schenker JG, Weinstein D. Ovarian hyperstimulation syndrome: a current survey. Fertil Steril 1978; 30: 255-268.
3. Ferraretti AP, Gianaroli L, Diotallevi L, Festi C, Trounsen A. Dopamine treatment for severe ovarian hyperstimulation syndrome. Hum Reprod 1992; 7: 180-183.
4. Morris RS, Paulson RJ. Ovarian hyperstimulation syndrome: classification and management. Contemp Obstet Gynecol 1994; 39: 43-54.
5. Knox GE. Antihistamine blockade of the ovarian hyperstimulation syndrome. Am J Obstet Gynecol 1974; 118: 992-994.
6. Yuen BH, McComb P, Yarali H, Fleige-Zahradka B-G. The ascites in the ovarian hyperstimulation syndrome does not originate from the ovary. Fertil Steril 1993; 59: 657-661.
7. Zaidise I, Friedman M, Lindenbaum ES, Askenazi R, Peretz BA, Paldi E. Serotonin and the ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol 1983; 15: 55-60.
8. Friedlander MA, Loret de Mola JR, Goldfarb JM. Elevated levels of interleukin-6 in ascites and serum from women with ovarian hyperstimulation syndrome. Fertil Steril 1993; 60: 826-833.
9. Morris RS, Paulson RJ. The ovarian renin angiotensin system: recent advances and their relationship to assisted reproductive technologies. Assisted Reprod Rev 1993; 3: 2-10.
10. Pride SM, Yuen BH, Moon YS, Leung PC. Relationship of gonadotropin-releasing hormone, danazol and prostaglandin blockade to ovarian enlargement and ascites formation of the ovarian hyperstimulation syndrome in the rabbit. Am J Obstet Gynecol 1986; 154: 1155-1160.
11. Tulandi T, Mcinnes RA, Arronet GH. Ovarian hyperstimulation syndrome following ovulation induction with hMG. Int J Fertil 1984; 29: 113-117.
12. Herman A, Ron-El R, Golan A, Raziel A, Soffer Y, Caspi E. Pregnancy rate and ovarian stimulation after luteal human chorionic gonadotropin in in vitro fertilization stimulated with gonadotropin-releasing hormone analog and menotropins. Fertil Steril 1990; 53: 92-96.
13. Rabau E, Serr DM, David A, Mashiach S, Lunenfeld B. Human menopausal gonadotropins for anovulation and sterility. Am J Obstet Gynecol 1967; 98: 92-98.
14. Rizk B, Smitz J. Ovarian hyperstimulation syndrome after superovulation using GnRH agonists for IVF and related procedures. Hum Reprod 1992; 7: 320-327.
15. Golan A, Ron-El R, Herman A, Soffer Y, Weinraab Z, Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv 1989; 6: 430-440.
16. Sauer MV, Ary BA, Paulson RJ. The demographic characterization of women participating in oocyte donation: a review of 300 consecutively performed cycles. Int J Gynecol Obstet 1994; 45: 147-151.
17. Asch RH, Li HP, Balmaceda JP, Weekstein LN, Stone SC. Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups. Hum Reprod 1991; 6: 1395-1399.
18. Navot D, Relou A, Birkenfeld A, Rabinowitz R, Brzezinski A, Margalioth EJ. Risk factors and prognostic variables in the ovarian hyperstimulation syndrome. Am J Obstet Gynecol 1988; 159: 210-215.
19. Haning RV, Strawn EY, Nolten WE. Pathophysiology of the ovarian hyperstimulation syndrome. Obstet Gynecol 1985; 66: 220-224.
20. Hackett RJ, Seifer DB, Haning RV. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors. Hum Reprod 1994; 9: 792-799.
21. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992; 58: 249-261.
22. Wong IL, Morris RS, Legro RS, Lobo RA, Paulson RJ, Sauer MV. Isolated polycystic morphology in ovum donors predicts response to controlled hyperstimulation. Hum Reprod 1995; 10: 524-528.
23. Lessing JB, Amit A, Libal Y, Yovel I, Kogosowski A, Peyser MR. Avoidance of cancellation of protocol hyperstimulation cycles by conversion to in-vitro fertilization-embryo transfer. Fertil Steril 1991; 56: 75-78.
24. Morris RS, Paulson RJ. Ovarian derived prorenin-angiotensin cascade in human reproduction. Fertil Steril 1994; 62: 1105-1114.
25. Morris RS, Paulson RJ, Lindheim SR, Legro RS, Lobo RA, Sauer MV. Angiotensin converting enzyme inhibition reverts luteal phase steroid production in oocyte donors. Fertil Steril 1995; 63: 854-858.
26. Asch RH, Ivery G, Goldsman M, Frederick JL, Stone SC, Balmaceda JP. The use of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome. Hum Reprod 1993; 8: 1015-1020.
27. Urman B, Pride SM, Yuen BH. Management of overstimulated gonadotropin cycles with a controlled drift period. Hum Reprod 1992; 7: 213-217.